Keya Medical Technology Co.

Seattle, Washington, USA, and Beijing, China (with offices in Shanghai and Shenzhen) [1, 2, 4, 5, 6, 7, 8, 16]  All China companies → — Founded 2016
Imaging AI Specialist Specialty-Focused AI
Cardiology Cardiothoracic Surgery Radiology
Cardiology AI Radiology & Imaging AI
Series D (last reported Series D funding in January 2021) [11]

Products

DEEPVESSEL Plaque
Keya Medical Technology Co., Ltd.
Cardiology AI
An AI software platform for coronary plaque analysis and quantification from CT angiography.

See all 1 product →

About Keya Medical Technology Co.

Keya Medical Technology Co. is an international medical technology company specializing in deep learning-based AI solutions for non-invasive disease diagnosis and treatment. The company, founded in 2016, develops AI-enabled diagnostic devices that aim to enhance efficiency, accuracy, and precision in healthcare across various specialties, including cardiology, neurology, pulmonology, pathology, and surgery. [2, 4, 8, 14]

Keya Medical’s flagship product, DEEPVESSEL FFR, is a CT-derived fractional flow reserve (CT-FFR) analysis software. This non-invasive tool utilizes deep learning technology to perform physiological functional assessments of coronary arteries from coronary computed tomography angiography (CCTA) scans. [17, 18] This software provides quantitative measurements of plaque volume, stenosis severity, and CAD-RADS categorization. [17] Keya Medical collaborates with hospitals and key opinion leaders globally, with its products being used in numerous hospitals and cardiac care centers. [4, 6, 11, 12]

Focus Areas

medical imaging AI deep learning diagnostic assistance cardiovascular AI neurological AI oncology AI

Business Intelligence

Technologycloud-native AI platform, deep learning algorithms

What Physicians Need to Know

Medical Imaging AI & Deep Learning
Keya Medical specializes in deep learning algorithms for medical imaging and bioinformatics. Their solutions are FDA-cleared and leverage AI to enhance diagnostic accuracy and efficiency.
Cardiovascular AI
A primary focus is on cardiovascular care, offering FDA-cleared deep learning solutions for comprehensive coronary CTA assessment. This includes quantitative plaque analysis (DEEPVESSEL Plaque) and CT-derived fractional flow reserve (DEEPVESSEL FFR) to support clinical decision-making from a single CCTA examination.
Diagnostic Assistance
Their flagship product, DEEPVESSEL FFR, provides a non-invasive physiological functional assessment of coronary arteries, aiming to reduce unnecessary invasive procedures like coronary angiography and stent implantation.
Neurological AI
Keya Medical has developed AI software for triaging time-sensitive intracranial hemorrhage from head CT scans.
Oncology AI
While their primary focus is cardiovascular, Keya Medical's broader commitment extends to developing AI-enabled diagnostic devices across various specialties, including oncology.
Key Differentiators
Key differentiators include FDA-cleared, deep learning-based solutions for non-invasive functional assessment (DEEPVESSEL FFR) and quantitative plaque analysis (DEEPVESSEL Plaque) from CCTA. Their technology offers high diagnostic accuracy, comprehensive anatomical and functional information, and a streamlined workflow.
Technology Stack
Keya Medical utilizes cutting-edge deep learning neural networks and algorithms for medical image processing, model reconstruction, and intelligent optimization. Their solutions are cloud-based, allowing for secure image transfer and efficient analysis.
Physician Tip

For physicians, Keya Medical's solutions offer precise, comprehensive, and efficient tools for diagnosing and managing cardiovascular disease. DEEPVESSEL FFR provides non-invasive functional assessment from CCTA, potentially reducing the need for invasive procedures. The interactive 3D models and detailed reports allow for quick identification of lesions and comprehensive observation of vascular structures, supporting confident clinical decision-making. The cloud-based platform and streamlined workflow eliminate the need for extensive software investments or staff training, making it convenient and cost-effective to integrate into daily practice.

Keya Medical's solutions are designed for seamless integration into existing clinical workflows. Studies can be securely uploaded to a cloud platform (e.g., PIA Cloud), automatically routed for analysis, and comprehensive reports, including interactive 3D models and FFR values, are promptly returned to the client's Picture Archiving and Communication System (PACS). They also collaborate with partners like Precision Image Analysis (PIA) and Corazon Imaging to offer cloud-based, on-demand post-processing services and integrate CT FFR into mobile radiology services.

Products by Keya Medical Technology Co.

1 product in the directory

DEEPVESSEL Plaque
Keya Medical Technology Co., Ltd.
Cardiology AI
An AI software platform for coronary plaque analysis and quantification from CT angiography.

Videos

News, demos, and interviews about Keya Medical Technology Co..

Loading videos...

Videos load interactively. If none appear, search YouTube for Keya Medical Technology Co. →

View all on YouTube

No press coverage or publications on file yet. Know of some? Suggest an edit →

Frequently Asked Questions

Keya Medical Technology Co. primarily offers AI-powered solutions for cardiovascular imaging and diagnostics. Their flagship product, DEEPVESSEL FFR, is an FDA-cleared, CE-marked, NMPA-approved, and HSA-certified software that uses deep learning to non-invasively assess coronary artery function from CT angiography (CCTA) scans. They also have DeepVessel Plaque, an FDA-cleared AI-powered tool for quantitative coronary plaque analysis from CCTA. While their primary focus is cardiovascular, Keya Medical is also developing AI-enabled diagnostic devices for neurology, pulmonology, pathology, and surgery, and previously received FDA clearance for intracranial hemorrhage triage software.
Keya Medical's flagship product, DEEPVESSEL FFR, has received significant international regulatory clearances, including FDA clearance in the US (2022), CE Mark in Europe (2018), NMPA approval in China (2020), and HSA certification in Singapore (2023). Their DeepVessel Plaque software also received FDA 510(k) clearance in 2026. These certifications demonstrate their adherence to stringent safety, effectiveness, and quality standards for commercial availability in these regions.
Keya Medical ensures accuracy and clinical validation through multi-center studies. For example, DEEPVESSEL FFR's diagnostic performance was validated in the ADAPT study, a multi-national, multi-center clinical trial involving 269 patients across 10 clinical sites in the US and EU. This study demonstrated good diagnostic performance in detecting ischemic conditions compared to invasive FFR measurements. Similarly, DeepVessel Plaque's FDA clearance was supported by a multicenter clinical validation study at three U.S. sites, showing strong agreement with expert consensus for plaque quantification and CAD-RADS categorization.
Keya Medical actively pursues strategic partnerships to expand its reach and integrate its AI solutions. They collaborate with companies like Precision Image Analysis (PIA) and Corazon Imaging to offer cloud-based, on-demand post-processing services for their AI FFR CT solution, eliminating the need for expensive software investments. They also partner with organizations like Kanbai Tech to further implement their CT-FFR technology in new markets, such as Spain, leveraging their distribution networks. These partnerships aim to streamline diagnostic workflows, improve patient care, and provide accessible cloud technology and mobile radiology services.
Keya Medical, founded in 2016, has demonstrated financial stability, securing over $111.74 million in funding, including a $46 million Series D round in 2021. This funding supports their AI product development and global business expansion. The company has a long-term vision of developing deep learning-based medical devices across various specialties, with a primary focus on cardiovascular care, and has established an AI diagnostic laboratory. They are committed to continuous innovation and have a pipeline of 11 products in development.

Related Companies

AZmed is a European MedTech company that develops artificial intelligence (AI) solutions for medical imaging, aiming to optimize physicians’ workflows and extend their capabilities. Rayvolve’s capabilities include detecting various types of fractures on standard X-rays (AZtrauma), identifying chest abnormalities (AZchest), performing standardized orthopedic measurements (AZmeasure), and estimating skeletal maturity (AZboneage). AZmed’s solutions are integrated into […]

Exo Imaging is a pioneering healthcare AI company dedicated to modernizing medical imaging through its high-performance handheld ultrasound platform and artificial intelligence. The company’s mission is to make high-quality, affordable, and easy-to-use medical imaging accessible to healthcare professionals worldwide, enabling them to make critical, real-time decisions that ultimately improve patient outcomes. Exo’s technology combines advances […]

The Yale School of Medicine is a leading institution dedicated to advancing science and medicine through discovery, both in the laboratory and at the bedside. It focuses on educating and nurturing future leaders by cultivating a dynamic, inclusive community that promotes curiosity and critical inquiry in an environment of scientific rigor. The institution applies advanced […]

Pixelplan Medical is an AI-native surgical operating system designed to enhance surgical planning, execution, and outcomes through GPU-accelerated AI. The platform unifies the entire surgical journey, from pre-operative planning to intra-operative guidance and post-operative analytics, providing a comprehensive solution for surgeons and institutions. It aims to address the challenge of unanalyzed surgical data and the […]

Indica Labs is a global leader in AI-powered digital pathology software and services, providing comprehensive solutions for quantitative evaluation and management of whole slide images. Their flagship platforms, HALO® and HALO AI, leverage artificial intelligence and computer vision algorithms to enable fast and precise analysis of tissue samples, which is critical for advancing research and […]

Hexoskin, founded in 2006, is a leader in non-invasive sensors, software, data science, and AI-driven health solutions. The company provides innovative technologies to professionals in pharmaceuticals, healthcare, defense, space, and aerospace, with a mission to make precise health data accessible and useful. They developed the first washable smart shirts in 2013, revolutionizing real-time physiological monitoring. […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.